SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+36.98%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$290M
AUM Growth
+$290M
(+23%)
Cap. Flow
+$29.5M
Cap. Flow
% of AUM
10.15%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
98
New
24
Increased
37
Reduced
19
Closed
12
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$14.5M |
| 2 |
Nuvalent
NUVL
|
$7.79M |
| 3 |
Terns Pharmaceuticals
TERN
|
$6.98M |
| 4 |
Biogen
BIIB
|
$6.09M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$5.5M |
Top Sells
| 1 |
Veracyte
VCYT
|
$11.1M |
| 2 |
Akero Therapeutics
AKRO
|
$7.01M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$6.26M |
| 4 |
Cogent Biosciences
COGT
|
$4.94M |
| 5 |
Nkarta
NKTX
|
$4.77M |
Sector Composition
| 1 | Healthcare | 96.19% |
| 2 | Technology | 0.09% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $14.5M | 4.14% | +49,898 | New | +$14.5M |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $14M | 4.02% | 1,707,370 +51,595 | +3% | +$424K |
|
|
PSTX
3
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $11.8M | 3.38% | 2,230,000 -324,277 | -13% | -$1.72M |
|
|
VRAY
4
DELISTED
ViewRay, Inc.
VRAY
| $10.8M | 3.08% | 2,405,360 +81,294 | +3% | +$364K |
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $10M | 2.86% | 253,655 +7,663 | +3% | +$302K |
|
|
6
Akero Therapeutics
AKRO
$3.74B
| $9.43M | 2.7% | 172,100 -127,900 | -43% | -$7.01M |
|
7
Immunovant
IMVT
$2.56B
| $9.22M | 2.64% | 519,614 +219,614 | +73% | +$3.9M |
|
|
8
Nuvalent
NUVL
$5.52B
| $9.02M | 2.58% | 302,963 +261,524 | +631% | +$7.79M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.95M | 2.56% | 334,535 +10,114 | +3% | +$271K |
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.95M | 2.56% | 37,652 +5,107 | +16% | +$1.21M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.43M | 2.13% | 140,366 +4,240 | +3% | +$224K |
|
12
Oric Pharmaceuticals
ORIC
$994M
| $7.28M | 2.08% | 1,236,296 +27,304 | +2% | +$161K |
|
|
13
Terns Pharmaceuticals
TERN
$609M
| $7.13M | 2.04% | 700,000 +685,527 | +4,737% | +$6.98M |
|
14
Mersana Therapeutics
MRSN
$36.5M
| $6.68M | 1.91% | 1,140,182 +146,109 | +15% | +$856K |
|
|
15
Biogen
BIIB
$19.4B
| $6.09M | 1.74% | +21,975 | New | +$6.09M |
|
16
Cerus
CERS
$251M
| $5.96M | 1.71% | 1,634,014 +17,555 | +1% | +$64.1K |
|
17
CVRx
CVRX
$205M
| $5.77M | 1.65% | 314,584 +6,664 | +2% | +$122K |
|
18
Aclaris Therapeutics
ACRS
$209M
| $5.55M | 1.59% | 352,193 -191,583 | -35% | -$3.02M |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $5.5M | 1.57% | +50,000 | New | +$5.5M |
|
|
CINC
20
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $4.86M | 1.39% | +395,382 | New | +$4.86M |
|
21
GSK
GSK
$79.9B
| $4.79M | 1.37% | +136,178 | New | +$4.79M |
|
|
22
Veracyte
VCYT
$2.39B
| $4.75M | 1.36% | 200,000 -465,854 | -70% | -$11.1M |
|
23
Krystal Biotech
KRYS
$4.27B
| $4.64M | 1.33% | 58,535 +1,890 | +3% | +$150K |
|
24
BioAtla
BCAB
$26.7M
| $4.51M | 1.29% | 546,875 +346,453 | +173% | +$2.86M |
|
25
United Therapeutics
UTHR
$13.8B
| $4.46M | 1.28% | 16,048 +5,352 | +50% | +$1.49M |
|